MX2016009597A - Terapias para el influenzavirus a subtipo h7n9. - Google Patents
Terapias para el influenzavirus a subtipo h7n9.Info
- Publication number
- MX2016009597A MX2016009597A MX2016009597A MX2016009597A MX2016009597A MX 2016009597 A MX2016009597 A MX 2016009597A MX 2016009597 A MX2016009597 A MX 2016009597A MX 2016009597 A MX2016009597 A MX 2016009597A MX 2016009597 A MX2016009597 A MX 2016009597A
- Authority
- MX
- Mexico
- Prior art keywords
- influenza
- therapies
- virus antibodies
- virus
- antibodies
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 2
- 206010064097 avian influenza Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000037797 influenza A Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona anticuerpos antiinfluenzavirus A efectivos en la unión, neutralización y tratamiento de influenzavirus A subtipo H7N9, composiciones que comprenden esos anticuerpos y métodos de uso de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461931949P | 2014-01-27 | 2014-01-27 | |
PCT/US2015/012942 WO2015112994A1 (en) | 2014-01-27 | 2015-01-26 | H7n9 influenza a therapies with anti-h7 virus antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016009597A true MX2016009597A (es) | 2016-10-13 |
Family
ID=52463191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009597A MX2016009597A (es) | 2014-01-27 | 2015-01-26 | Terapias para el influenzavirus a subtipo h7n9. |
Country Status (10)
Country | Link |
---|---|
US (1) | US9879066B2 (es) |
EP (1) | EP3099710A1 (es) |
JP (1) | JP2017508002A (es) |
KR (1) | KR20160111948A (es) |
CN (1) | CN105934443A (es) |
BR (1) | BR112016015078A2 (es) |
CA (1) | CA2931012A1 (es) |
MX (1) | MX2016009597A (es) |
RU (1) | RU2682049C2 (es) |
WO (1) | WO2015112994A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
US10513553B2 (en) | 2015-11-13 | 2019-12-24 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
CN106519027B (zh) * | 2016-11-11 | 2019-09-17 | 深圳先进技术研究院 | 抗h7n9全人源单克隆抗体5j13及其制法与应用 |
CN109988236B (zh) * | 2017-12-30 | 2022-04-01 | 中国科学院天津工业生物技术研究所 | 一种流感病毒抗体的应用 |
EP3946613A1 (en) | 2019-03-25 | 2022-02-09 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030219442A1 (en) * | 2002-03-13 | 2003-11-27 | Toshifumi Mikayama | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
US7981930B2 (en) * | 2007-03-13 | 2011-07-19 | Adamas Pharmaceuticals, Inc. | Compositions and kits for treating influenza |
CA2761648C (en) * | 2009-05-11 | 2019-03-12 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
RU2500426C2 (ru) * | 2010-02-27 | 2013-12-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1, и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1 |
DK2731967T3 (en) * | 2011-07-14 | 2017-01-16 | Janssen Vaccines & Prevention Bv | HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUS FROM PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUS |
US9868952B2 (en) * | 2012-07-08 | 2018-01-16 | Sirnaomics, Inc. | Compositions and methods for “resistance-proof” SiRNA therapeutics for influenza |
ES2701746T3 (es) * | 2012-11-13 | 2019-02-25 | Hoffmann La Roche | Anticuerpos antihemaglutinina y procedimientos de uso |
CN103450350B (zh) * | 2013-07-30 | 2015-07-01 | 中国人民解放军军事医学科学院基础医学研究所 | 人感染h7n9禽流感表位抗原及其在免疫检测试剂中的用途 |
-
2015
- 2015-01-21 RU RU2016128223A patent/RU2682049C2/ru not_active IP Right Cessation
- 2015-01-26 BR BR112016015078A patent/BR112016015078A2/pt not_active IP Right Cessation
- 2015-01-26 EP EP15703392.9A patent/EP3099710A1/en not_active Withdrawn
- 2015-01-26 KR KR1020167022122A patent/KR20160111948A/ko not_active Application Discontinuation
- 2015-01-26 MX MX2016009597A patent/MX2016009597A/es unknown
- 2015-01-26 CN CN201580005857.5A patent/CN105934443A/zh active Pending
- 2015-01-26 JP JP2016566869A patent/JP2017508002A/ja not_active Ceased
- 2015-01-26 CA CA2931012A patent/CA2931012A1/en not_active Abandoned
- 2015-01-26 WO PCT/US2015/012942 patent/WO2015112994A1/en active Application Filing
-
2016
- 2016-07-21 US US15/215,738 patent/US9879066B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP3099710A1 (en) | 2016-12-07 |
CA2931012A1 (en) | 2015-07-30 |
KR20160111948A (ko) | 2016-09-27 |
JP2017508002A (ja) | 2017-03-23 |
RU2016128223A3 (es) | 2018-08-13 |
US20170114121A1 (en) | 2017-04-27 |
CN105934443A (zh) | 2016-09-07 |
WO2015112994A1 (en) | 2015-07-30 |
BR112016015078A2 (pt) | 2018-01-23 |
RU2016128223A (ru) | 2018-03-05 |
RU2682049C2 (ru) | 2019-03-14 |
US9879066B2 (en) | 2018-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202107931B (en) | Anti-tau antibodies and methods of use | |
PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
MX2022001043A (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas. | |
PH12017502180A1 (en) | Tau-binding antibodies | |
MX2020002694A (es) | Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas. | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
PH12017502207A1 (en) | Tau-binding antibodies | |
MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
MX2022001220A (es) | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. | |
MX2016009597A (es) | Terapias para el influenzavirus a subtipo h7n9. | |
MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
MX2016015280A (es) | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. | |
MX2018003040A (es) | Metodos para el tratamiento de formas recurrentes de esclerosis multiple. | |
NZ744340A (en) | Anti-jagged1 antibodies and methods of use | |
TH1601002905A (th) | วิธีการและองค์ประกอบสำหรับการดัดแปลงที่มีเป้าหมายของจีโนม |